

# Andreas Engert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3300638/publications.pdf>

Version: 2024-02-01

77  
papers

4,703  
citations

304743

22  
h-index

98798

67  
g-index

78  
all docs

78  
docs citations

78  
times ranked

4622  
citing authors

#	ARTICLE	IF	CITATIONS
1	Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group. <i>Leukemia</i> , 2022, 36, 580-582.	7.2	12
2	9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAH trial. <i>British Journal of Haematology</i> , 2022, 196, 116-126.	2.5	9
3	Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma. <i>Leukemia</i> , 2022, 36, 760-771.	7.2	14
4	Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis. <i>Leukemia</i> , 2022, 36, 772-780.	7.2	6
5	Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabine and cisplatin in patients with relapsed or refractory classical Hodgkin lymphoma: an experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD18). <i>British Journal of Haematology</i> , 2022, 196, 606-616.	2.5	4
6	Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma. <i>Infection</i> , 2022, , 1.	4.7	0
7	Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. <i>Hematological Oncology</i> , 2022, 40, 801-804.	1.7	6
8	Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2022, 197, .	2.5	0
9	Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysis. <i>British Journal of Haematology</i> , 2022, 198, 401-404.	2.5	5
10	Relapse After Early-Stage, Favorable Hodgkin Lymphoma: Disease Characteristics and Outcomes With Conventional or High-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, 107-115.	1.6	5
11	Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAH Trial. <i>Clinical Cancer Research</i> , 2021, 27, 402-407.	7.0	20
12	Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group. <i>British Journal of Haematology</i> , 2021, 193, 515-519.	2.5	5
13	Hodgkin Lymphoma: Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 1125.	2.4	24
14	Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG) Tj ETQq0 0 0 rgBt/Overlork 10 Tf 50		
15	PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e398-e409.	4.6	28
16	Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP. <i>Leukemia</i> , 2021, 35, 3589-3593.	7.2	8
17	Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Current Opinion in Oncology</i> , 2021, 33, 395-399.	2.4	2
18	Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 900-906.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Histopathological growth patterns in patients with advanced nodular lymphocyte-predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group. <i>British Journal of Haematology</i> , 2021, , .	2.5	4
20	Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer. <i>European Journal of Cancer</i> , 2021, 155, 281-290.	2.8	4
21	In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection. <i>Med</i> , 2021, 2, 1171-1193.e11.	4.4	24
22	Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group. <i>Leukemia</i> , 2020, 34, 953-956.	7.2	14
23	Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. <i>Blood</i> , 2020, 136, 2851-2863.	1.4	47
24	How I treat nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2020, 136, 2987-2993.	1.4	30
25	Steering Chimeric Antigen Receptor T Cells Into the Hodgkin Lymphoma Niche. <i>Journal of Clinical Oncology</i> , 2020, 38, 3816-3818.	1.6	3
26	Lymphocyte predominant cells detect <i>Moraxella catarrhalis</i> -derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma. <i>Nature Communications</i> , 2020, 11, 2465.	12.8	31
27	Reply to H.J.A. Adams et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 1116-1117.	1.6	0
28	Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 2839-2848.	1.6	28
29	PET positivity – the agony of choice: response assessment and interpretation of increased FDG uptake of residual mediastinal tissue after frontline therapy in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 251-254.	1.3	2
30	Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies. <i>The Cochrane Library</i> , 2020, 2020, CD012643.	2.8	18
31	Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma. <i>JAMA Oncology</i> , 2020, 6, 872.	7.1	112
32	Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication. <i>Blood</i> , 2020, 136, 8-8.	1.4	1
33	The time to relapse correlates with the histopathological growth pattern in nodular lymphocyte predominant Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1208-1213.	4.1	25
34	Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3528-3537.	1.6	26
35	Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 2835-2845.	1.6	151
36	Predictive Value of Positron Emission Tomography/Computed Tomography After ABVD-Based Chemotherapy in Early-Stage Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3324-3325.	1.6	2

#	ARTICLE	IF	CITATIONS
37	Treatment of elderly Hodgkin lymphoma patients. <i>Hematological Oncology</i> , 2019, 37, 92-94.	1.7	12
38	Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center. <i>HemaSphere</i> , 2019, 3, e293.	2.7	5
39	Introducing the HemaSphere Controversies Series. <i>HemaSphere</i> , 2019, 3, e296.	2.7	1
40	Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma (AERN): An International Multicenter Single-Arm Two-Stage Phase II GHSG Trial. <i>Blood</i> , 2019, 134, 1547-1547.	1.4	10
41	Balancing risk and benefit in early-stage classical Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 1666-1678.	1.4	36
42	Outcome of Patients With Early-Stage Infradiaphragmatic Hodgkin Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. <i>Journal of Clinical Oncology</i> , 2018, 36, 2603-2611.	1.6	7
43	Hodgkin Lymphoma in Adults. <i>Deutsches Arzteblatt International</i> , 2018, 115, 535-540.	0.9	21
44	Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 1999-2007.	1.6	108
45	Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 1444-1450.	1.6	32
46	Cancer-Related Fatigue in Patients With and Survivors of Hodgkin Lymphoma: The Impact on Treatment Outcome and Social Reintegration. <i>Journal of Clinical Oncology</i> , 2016, 34, 4329-4337.	1.6	70
47	Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group. <i>Lancet Oncology</i> , The, 2016, 17, 1453-1462.	10.7	91
48	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1283-1294.	10.7	818
49	CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, <i>in vitro</i> . <i>Oncotarget</i> , 2016, 7, 30523-30535.	1.8	43
50	Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. <i>Lancet</i> , The, 2015, 385, 1418-1427.	13.7	154
51	Relapse Analysis of Irradiated Patients Within the HD15 Trial of the German Hodgkin Study Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 46-53.	0.8	23
52	Significant dose Escalation of Idarubicin in the treatment of aggressive Non-Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL. <i>SpringerPlus</i> , 2014, 3, 5.	1.2	7
53	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2183-2189.	1.6	1,332
54	CD30-Targeted Therapy with Brentuximab Vedotin Combined with Donor Lymphocyte Infusions Induce Sustained Clinical Remissions and Tumor Specific Immunity in a Series of Patients with Relapsed Hodgkin Lymphoma After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4213-4213.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Fertility and Gonadal Function After Treatment of Early Unfavorable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG). <i>Blood</i> , 2011, 118, 432-432.	1.4	1
56	Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2010, 363, 640-652.	27.0	824
57	Preventing Infections in Cancer Patients: Antibiotics, Hematopoetic Growth Factors or Both? a Network Analysis. <i>Blood</i> , 2008, 112, 1315-1315.	1.4	1
58	Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. <i>Blood</i> , 2008, 112, 367-367.	1.4	9
59	Long-Term Disease Control in Patients with Primary Central Nervous System Lymphoma. <i>Blood</i> , 2008, 112, 3600-3600.	1.4	0
60	Quality of Life in a 2-Year Follow-up: Signs of PNP Predicting Cognitive Functioning in Survivors Treated in the HD10â€“12 Trials of the German Hodgkin Study Group (GHSG).. <i>Blood</i> , 2008, 112, 1455-1455.	1.4	0
61	EXTEND PIX301: A Phase III Randomized Trial of Pixantrone Versus Other Chemotherapeutic Agents as Third-Line Monotherapy in Patients with Relapsed, Aggressive Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 7, 152-154.	1.4	14
62	Bortezomib Is Not Active in Patients with Relapsed Hodgkinâ€™s Lymphoma: Results of a Prematurely Closed Phase II Study.. <i>Blood</i> , 2006, 108, 2477-2477.	1.4	2
63	Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. <i>Haematologica</i> , 2006, 91, 546-9.	3.5	27
64	Hodgkin's Lymphoma in Elderly Patients: A Comprehensive Retrospective Analysis From the German Hodgkin's Study Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 5052-5060.	1.6	169
65	Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkinâ€™s Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 1522-1529.	1.6	123
66	Trends and Socio-Economic Inequalities in Cancer Survival of Patients with Hodgkinâ€™s Lymphoma Diagnosed in England and Wales between 1986 and 1999.. <i>Blood</i> , 2005, 106, 749-749.	1.4	5
67	A Comparison of Outcome and Second Malignancies in Adolescents and Adult Patients with Hodgkinâ€™s Lymphoma (HL). Results from the German Hodgkin Study Group.. <i>Blood</i> , 2005, 106, 2670-2670.	1.4	0
68	Identification of Prognostic Factors in Patients with Early Stage Unfavorable Hodgkinâ€™s Lymphoma: An Individual Patient Data Meta-Analysis.. <i>Blood</i> , 2005, 106, 5577-5577.	1.4	0
69	Reporting of Randomised Controlled Trials in Hodgkinâ€™s Lymphoma from 1966 to 2002. A Pre- and after CONSORT Evaluation.. <i>Blood</i> , 2005, 106, 1336-1336.	1.4	0
70	Pegfilgrastim Supports Delivery of BEACOPP Chemotherapy Administered Every 14 Days.. <i>Blood</i> , 2004, 104, 1316-1316.	1.4	1
71	FluCamâ€™a New, 4-Weekly Combination of Fludarabine and Alemtuzumab for Patients with Relapsed Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2004, 104, 2517-2517.	1.4	4
72	Cologne High-Dose Sequential Chemotherapy in Relapsed and Refractory Hodgkin Lymphoma - Results of a Large Multicenter Study of the German Hodgkin Lymphoma Study Group (GHSG).. <i>Blood</i> , 2004, 104, 309-309.	1.4	1

#	ARTICLE	IF	CITATIONS
73	Secondary Amenorrhoea after Hodgkin's Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives during Therapy: A Report from the German Hodgkin Lymphoma Study Group (GHSG).. Blood, 2004, 104, 1314-1314.	1.4	8
74	Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. , 2000, 86, 718-724.		24
75	Use of G-CSF for granulocyte transfusion therapy. Cytokines, Cellular & Molecular Therapy, 2000, 6, 89-95.	0.3	8
76	Recombinant Human Erythropoietin as an Alternative to Blood Transfusion in Cancer-Related Anaemia. Disease Management and Health Outcomes, 2000, 8, 259-272.	0.4	22
77	Non-Hodgkin's Lymphoma. BioDrugs, 1997, 8, 216-234.	4.6	2